Skip to main content
Article thumbnail
Location of Repository

In Vitro Activity of Iclaprim against Respiratory and Bacteremic Isolates of Streptococcus pneumoniae▿

By George G. Zhanel and James A. Karlowsky

Abstract

Iclaprim, a novel dihydrofolate reductase inhibitor, inhibited 90% of the clinical isolates (MIC90) of Streptococcus pneumoniae (n = 785) collected by a national surveillance program at a concentration of 1 μg/ml. The MIC90 for iclaprim was 7 doubling dilutions lower for trimethoprim-sulfamethoxazole-susceptible isolates (n = 670; MIC90, 0.06 μg/ml) than for trimethoprim-sulfamethoxazole-resistant isolates (n = 115; MIC90, ≥8 μg/ml). The potential clinical utility of iclaprim to treat patients with pneumococcal infections may depend upon the current prevalence of resistance to trimethoprim-sulfamethoxazole in this pathogen

Topics: Susceptibility
Publisher: American Society for Microbiology (ASM)
OAI identifier: oai:pubmedcentral.nih.gov:2663069
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.